Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 24 of 36 / 848 articles
A growing community of 'biohackers' and productivity enthusiasts are experimenting with nicotine—in gum, lozenge, and patch form—as a cognitive enhancer, without any history of smoking. The practice is scientifically plausible and ethically contested.
Millions of smokers have reduced their cigarette consumption by supplementing with vaping—but haven't quit completely. The public health implications of 'dual use' are fiercely debated. The answer depends on whether dual use is a transitional state or a permanent destination.
Public health campaigns are designed by experts who have never smoked, for populations whose lives they don't share, using messages that don't resonate with the people they're trying to reach. The billion smokers who remain are not a 'problem' to be solved—they're a constituency to be served.
Behind every flavored vape is a global network of flavor chemists, extraction facilities, and regulatory arbitrageurs who turn raw botanicals into the thousands of flavor compounds that define the vaping experience. Their world is largely invisible to regulators—and to consumers.
As cannabis legalization spreads and cigarette consumption declines, the tobacco and cannabis industries are converging—through shared delivery technology, cross-industry investment, and an overlapping consumer base. The regulatory systems for the two substances remain entirely separate, and entirely unprepared.
Nicotine is a chronobiotic—a substance that affects the body's internal clock. Smokers have disrupted sleep architecture, altered circadian gene expression, and a distinctive temporal pattern of craving that peaks in the morning. Understanding the nicotine-circadian connection opens new avenues for cessation support.
An estimated 10-12% of cigarettes consumed globally are illicit—smuggled, counterfeited, or manufactured without tax payment. The illicit trade undermines every tobacco control policy, funds organized crime, and exposes consumers to unregulated products. Addressing it requires confronting uncomfortable truths.
Adolescent risk-taking is not a failure of information—it's a developmental feature. The public health campaigns designed to scare teenagers away from vaping may, in some cases, be making vaping more attractive to the very audience they're trying to reach.
American chewing tobacco—loose-leaf, 'dip,' and moist snuff—remains popular in rural communities, among military personnel, and in certain sports cultures, despite causing oral cancer at rates far higher than Swedish snus. The product's persistence reveals uncomfortable truths about culture, class, and regulation.
Menthol cigarettes account for over a third of the US cigarette market and are disproportionately used by Black smokers. The FDA's proposed menthol ban would be the most significant federal tobacco regulation in decades—with consequences that extend far beyond public health.
People with mental illness consume nearly half of all cigarettes sold in the United States. They are more nicotine-dependent, less likely to be offered cessation support, and more likely to die from smoking-related disease than the general population. The mental health system has largely accepted this as normal.
A vaccine that prevents nicotine from reaching the brain—making smoking unrewarding and relapse impossible—has been the holy grail of addiction medicine since the 1990s. The science is sound. The clinical trials have all failed. What happened?
In 1965, smoking was a habit of the affluent. Today, in high-income countries, it is overwhelmingly concentrated among the poor, the mentally ill, and the socially marginalized. The story of how smoking became a disease of poverty is a story about the limits of public health in the absence of social justice.
In the absence of adequate public health infrastructure for smoking cessation, vape shops have become de facto health clinics—staffed not by medical professionals but by former smokers who guide customers through the transition from cigarettes to vaping. The results are messy, unregulated, and surprisingly effective.
Altria—the parent company of Philip Morris USA, maker of Marlboro—has spent billions trying to diversify beyond cigarettes. The results have been catastrophic: Juul, Cronos, and a series of strategic missteps that raise fundamental questions about whether a cigarette company can meaningfully transform.
Genetic variation explains roughly 50% of the variance in smoking initiation, 60% of the variance in nicotine dependence severity, and 50% of the variance in cessation success. The era of personalized nicotine medicine is approaching—but its ethical implications are largely unexplored.
The FDA has the authority to mandate that all cigarettes sold in the US contain only minimally addictive levels of nicotine. The policy has bipartisan support and strong scientific rationale. It also raises questions about black markets, unintended consequences, and consumer autonomy.
New Zealand's 'smoke-free generation' law—banning cigarette sales to anyone born after 2008—was the most ambitious tobacco control policy ever enacted. Then a change of government repealed it. The experiment in generational prohibition reveals the limits of legislative ambition.
Swedish snus—a moist oral tobacco product—has driven Sweden's smoking rate below 5%, the lowest in Europe. Swedish men have Europe's lowest lung cancer mortality. And snus is banned in every EU country except Sweden. How did the evidence get so thoroughly ignored?
America tried banning alcohol in 1920. It ended in 1933, after thirteen years of black markets, organized crime, and public disillusionment. A century later, nicotine regulators are repeating history—and they seem not to have read it.
Long after nicotine receptors have downregulated and withdrawal has subsided, many ex-smokers still feel the phantom cigarette—the muscle memory of the hand-to-mouth ritual, the absence of the object between the fingers. Addiction lives in the body, not just the brain.
Smokers who quit gain an average of 4-5 kilograms in the first year. For many smokers—particularly women—the fear of weight gain is a more powerful deterrent to quitting than the fear of lung cancer. Addressing this barrier requires honesty, not reassurance.
Proponents and opponents of nicotine harm reduction cite the same scientific literature and reach opposite conclusions. The disagreement is not about the data—it's about what kind of evidence should count, and who gets to decide.
In 2015, a small startup called Juul introduced a nicotine formulation that would transform the vaping industry. Nicotine salts—created by adding benzoic acid to freebase nicotine—delivered a smoother, faster-acting experience. The chemistry was simple. The consequences were not.
Products
Select a product to view details, highlights, and technical specifications.
